NEWBORN SCREENING OF INFANTS AND NEWBORNS WITH CONGENITAL HYPOTHYROIDISM
Associate Professor Michelle Jack
Clinical Practice & Co-Lead Doctor of Medicine
Bond University, Queensland, Australia
RESEARCHER PROFILE
Filmed in Robina, Queensland | July 2024
Michelle Jack is Associate Professor of Clinical Practice, Faculty of Health Sciences & Medicine at Bond University, QLD and co-Head of Paediatrics and a Paediatric Endocrinologist at Lismore Base Hospital in NSW. She graduated from Medicine at the University of Queensland with first class honours and the University Gold Medal and has a PhD in hyperinsulinism from the University of QLD. She has postgraduate qualifications in higher education and is a fellow of the higher education academy.
Assoc Prof Jack is an experienced leader and practitioner in the healthcare, research and higher education sectors. Career highlights include: Head of Department Paediatric Endocrinology, Royal North Shore Hospital; Academic Lead Education & Partnerships, University Centre for Rural Health, University of Sydney; Head of the Beta Cell Laboratory, Kolling Institute; Chair Australasian Paediatric Endocrine Group scientific program organising committee and Co-Chair international scientific program organising committees; Chair Northern Sydney Adolescent Committee; International Research Fellowship, Juvenile Diabetes Research Foundation, Head of Research, Impact Institute.
Assoc Prof Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Assoc Prof Jack hopes to make a positive difference to the health and well-being of children and their families.
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Dr Kelly-Anne Masterman
RESEARCH IN BRAIN COMPUTER INTERFACE
@ SYNCHRON
MELBOURNE, VICTORIA, AUSTRALIA -
Precision and personalised nutrition
Laureate Professor Clare Collins is helping people access effective medical nutrition therapies that significantly reduce their risk of chronic disease. She and her team are developing innovative technologies, including apps and online programmes.
